GlassScriptPhysician profile
Jared Matthew Laino
NPI 1568981538
$10,101.96
in general payments reported to CMS, 2019-2025
28 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $3,110 · 2023: $1,983 · 2024: $1,964 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,137.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.69 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,078.06 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $992.61 | 2021-2025 | Caplyta |
| Alkermes, INC. | $852.53 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $835.41 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $797.48 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $718.86 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $712.68 | 2022-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $642.73 | 2021-2025 | Qelbree, Qelbree |
| Eisai INC. | $286.68 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $263.19 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $240.09 | 2021-2025 | Rexulti |
| Almatica Pharma LLC | $210.80 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $170.27 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $153.75 | 2022-2023 | Belsomra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $133.41 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $107.71 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $75.61 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $67.41 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $63.62 | 2022-2025 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $59.09 | 2022 | |
| Neos Therapeutics, LP | $54.43 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $42.96 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $30.37 | 2025 | Jornay Pm |
| Biogen, INC. | $19.24 | 2024 | |
| Adlon Therapeutics L.P. | $17.42 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.76 | 2022 | |
| Bausch Health US, LLC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Laino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.